Rituximab, dexamethasone, cytarabine, and oxaliplatin (R-DHAX) is an effective and safe salvage regimen in relapsed/refractory B-cell non-Hodgkin lymphoma
- PMID: 20709662
- DOI: 10.3816/CLML.2010.n.055
Rituximab, dexamethasone, cytarabine, and oxaliplatin (R-DHAX) is an effective and safe salvage regimen in relapsed/refractory B-cell non-Hodgkin lymphoma
Abstract
Background: Salvage therapy for patients with refractory/relapsed B-cell non-Hodgkin lymphoma (NHL) is based on polychemotherapy, followed by high-dose therapy and autologous stem cell transplantation in eligible patients (HDT/ASCT). R-DHAP combines rituximab with cisplatin, cytarabine, and dexamethasone.
Patients and methods: We substituted cisplatin with oxaliplatin to avoid nephrotoxicity and retrospectively analyzed a large series of 91 patients with refractory/relapsed B-cell NHL to evaluate toxicities, response rates (RRs), and survival. Median age at R-DHAX (rituximab/dexamethasone/cytarabine/oxaliplatin) treatment was 60 years (range, 28-82 years). Renal insufficiency was present in 18 patients. The most frequent histologic subtypes were diffuse large B-cell lymphoma (n = 42) and follicular lymphoma (n = 30). Seventeen patients (19%) were naive to rituximab at time of R-DHAX.
Results: Grade III/IV toxicities were mainly hematologic, including anemia (n = 9), neutropenia (n = 44), and thrombocytopenia (n = 47). Grade I/II neurologic toxicities, sensitive or motor, were observed, and these were mainly transient except for 3 cases of motor neuropathy associated with previous exposure to vincristine. Neither renal toxicities nor degradation of previous renal insufficiency were observed. The overall RR was 75%, with a complete RR of 57%, with no statistical difference between patients previously treated with rituximab versus without rituximab. At a median follow-up of 23 months, 2-year probability rates of overall survival and progression-free survival were 75% and 43%, respectively, with a significant difference between patients treated with HDT/ASCT and patients not eligible for HDT/ASCT.
Conclusion: R-DHAX is an efficient regimen in patients with relapsed/refractory B-cell NHL even in elderly patients if hematologic toxicities are closely managed.
Similar articles
-
Rituximab combined with DexaBEAM followed by high dose therapy as salvage therapy in patients with relapsed or refractory B-cell lymphoma: mature results of a phase II multicentre study.Br J Haematol. 2015 Mar;168(6):824-34. doi: 10.1111/bjh.13234. Epub 2014 Dec 28. Br J Haematol. 2015. PMID: 25546611 Clinical Trial.
-
Oxaliplatin-based chemotherapy (dexamethasone, high-dose cytarabine, and oxaliplatin)±rituximab is an effective salvage regimen in patients with relapsed or refractory lymphoma.Cancer. 2010 Oct 1;116(19):4573-9. doi: 10.1002/cncr.25216. Cancer. 2010. PMID: 20572029
-
Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma.Cancer Invest. 2008 May;26(4):401-6. doi: 10.1080/07357900701788098. Cancer Invest. 2008. PMID: 18443961
-
Is there any role for transplantation in the rituximab era for diffuse large B-cell lymphoma?Hematology Am Soc Hematol Educ Program. 2012;2012:410-6. doi: 10.1182/asheducation-2012.1.410. Hematology Am Soc Hematol Educ Program. 2012. PMID: 23233612 Review.
-
Treatment of relapsed/refractory paediatric aggressive B-cell non-Hodgkin lymphoma.Br J Haematol. 2020 Jun;189(5):826-843. doi: 10.1111/bjh.16461. Epub 2020 Mar 6. Br J Haematol. 2020. PMID: 32141616 Review.
Cited by
-
Translating the Biology of Diffuse Large B-cell Lymphoma Into Treatment.Oncologist. 2022 Feb 3;27(1):57-66. doi: 10.1093/oncolo/oyab004. Oncologist. 2022. PMID: 35305092 Free PMC article. Review.
-
Fulminant hepatitis due to very severe sinusoidal obstruction syndrome (SOS/VOD) after autologous peripheral stem cell transplantation: a case report.BMC Res Notes. 2018 Jul 3;11(1):436. doi: 10.1186/s13104-018-3533-0. BMC Res Notes. 2018. PMID: 29970140 Free PMC article.
-
Minimal renal toxicity after Rituximab DHAP with a modified cisplatin application scheme in patients with relapsed or refractory diffuse large B-cell lymphoma.BMC Cancer. 2016 Apr 11;16:267. doi: 10.1186/s12885-016-2289-y. BMC Cancer. 2016. PMID: 27067641 Free PMC article.
-
All-Oral Low-Dose Chemotherapy TEPIP is Effective and Well-Tolerated in Relapsed/Refractory Patients With Aggressive B-Cell Lymphoma.Front Oncol. 2022 May 10;12:852987. doi: 10.3389/fonc.2022.852987. eCollection 2022. Front Oncol. 2022. PMID: 35619924 Free PMC article.
-
Rituximab, gemcitabine, cisplatin, and dexamethasone in patients with refractory or relapsed aggressive B-cell lymphoma.Med Oncol. 2012 Dec;29(4):2409-16. doi: 10.1007/s12032-012-0211-2. Epub 2012 Apr 3. Med Oncol. 2012. PMID: 22476761
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical